Solis Names Polfreman President, CEO

imageSolis Women’s Health, the nation’s largest independent provider of screening and diagnostic imaging services for breast cancer, has appointed James Polfreman to the position of president and CEO. Polfreman will oversee the company as it continues to expand its nationwide network of facilities, which currently serve more than 400,000 patients in five states. “James has a track record of delivering world-class healthcare services in a highly competitive market while also producing exceptional bottom-line results,” says Solis Chairman Matthew Witte Solis Chairman Matthew Witte. “We look forward to the addition of his proven leadership skills as we seek to expand our platform in existing and new markets.” Prior to assuming the leadership of Solis, Polfreman served as CEO of the Retail Healthcare Businesses at the Memorial Herman Hospital System in Houston, Texas. During his seven-year tenure, he built the retail division from the ground up to become the city’s most profitable market leader in outpatient services. In this position, Polfreman oversaw a portfolio comprised of numerous freestanding imaging and breast centers, physical therapy clinics, ambulatory surgery centers, and laboratories with a total of 1,300 employees and net annual revenues of more than $350 million. Solis was founded on the premise that focusing exclusively on the detection of breast cancer, employing only experienced fellowship-trained breast physicians and utilizing state-of-the-art digital equipment produces significantly better outcomes. It is headquartered in Austin, Texas.
Julie Ritzer Ross,

Contributor

Around the web

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.